Cara Therapeutics, Inc

Cara Therapeutics, Inc Overview

Company Headquarter: Connecticut, US

Founded: 2004

Workforce: ~50

Company Working: Cara Therapeutics, Inc. is an emerging biotechnology company that develops novel therapeutics to treat pain, inflammation, and pruritus. It is a clinical-stage biotechnology company working on cannabinoid receptors to develop alternative treatment solutions for patients. The company’s advanced patented compound CR845 is undergoing various clinical tests for uremic pruritus and acute pain. Cara Therapeutics, Inc. has a group of medical experts, scientists, and industry leaders helping in providing innovative solutions to patients.

Strategy

Cara Therapeutics, Inc. focuses on research and development activities to launch new innovative products in the market. It is working with medical experts and scientists to develop quality products that can fulfill customer demands. The company’s customer-oriented approach will help the company gain a strong customer base in the future.

Company Snapshot

$198.9M

Revenue

50

Employees

2004

Founded

SWOT Analysis

Strengths

Strong R&D to focus to develop innovative products
Strong workforce of medical experts and scientists

Weaknesses

Most of the products are in various stages of the clinical trials

Opportunities

High demand for innovative products from end-users
Unmet medical needs in developing and underdeveloped regions

Threats

Growing competition from other companies
Stringent political and regulatory environment

Key Developments

Date	Approach	Development
September 2022	Announcement	Cara Therapeutics, Inc. announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. (Japan) submitted to Japan for approval of difelikefalin for the treatment of pruritus in hemodialysis patients.
April 2021	Announcement	Cara Therapeutics, Inc. announced topline results from its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA (difelikefalin tablets) to treat moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients.
May 2018	Agreement	Cara Therapeutics, Inc. signed an agreement of USD 540 million with Fresenius (Germany) and Vifor Pharma (Switzerland) in order to commercialize the Korsuva.

Product Offering

Cara Therapeutics, Inc
- Medical Cannabis Market

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.